A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Filgrastim (Filgrastim/SBS) 300 mcg SC injection relative to Filgrastim (Filgrastim/CIM) 300 mcg SC injection
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacokinetics
- Sponsors Siam Bioscience
- 15 Jan 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.
- 18 Jun 2018 New trial record